Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.63 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | CFD | P00746 | 2/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 2/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NOS3 | P29474 | 2/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5046678 | 0.98 | SLC7A5 (0.61) | SLC7A5LOXL2ALDH1A1GAAGFER | |
| Hydrochloric Acid SCHEMBL15709809 | 0.98 | SLC7A5 (0.61) | SLC7A5LOXL2ALDH1A1GAAGFER | |
| SCHEMBL12400239 | 0.91 | SLC7A5 (0.68) | SLC7A5LOXL2ALDH1A1GAAGFER | |
| SCHEMBL30559747 | 0.86 | SLC7A5 (0.60) | SLC7A5LOXL2ALDH1A1GAAGFER | |
| SCHEMBL6581681 | 0.86 | SLC7A5 (0.60) | SLC7A5LOXL2ALDH1A1GAAGFER | |
| SCHEMBL1987047 | 0.86 | SLC7A5 (0.63) | SLC7A5LOXL2ALDH1A1GAAGFER | |
| SCHEMBL4394735 | 0.85 | SLC7A5 (0.62) | SLC7A5ALDH1A1GAAGFERHSP90AB1 | |
| SCHEMBL4066292 | 0.85 | CYP4F2 (0.63) | SLC7A5LOXL2ALDH1A1GAAGFER | |
| Hydrochloric Acid SCHEMBL29112501 | 0.85 | SLC7A5 (0.58) | SLC7A5LOXL2ALDH1A1GAAGFER | |
| SCHEMBL7882515 | 0.84 | LOXL2 (0.51) | SLC7A5LOXL2ALDH1A1GAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023227666-A1 | PYRIMIDINONE COMPOUNDS FOR TREATING ACUTE INFLAMMATION | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | WO | disclosed |
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-03-30 | — | — | US | disclosed |
| US-11261201-B2 | TRNA synthetase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-01 | — | — | US | disclosed |
| US-11254644-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2022-02-22 | — | — | US | disclosed |
| EP-3186242-B1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S R L (IT) | 2021-10-06 | — | — | EP | disclosed |
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
| US-20200207721-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2020-07-02 | — | — | US | disclosed |
| EP-3456719-A1 | COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PFIZER INC. | 2005-09-15 | — | — | US | disclosed |
| WO-2004078169-A1 | USE OF EP2 SELECTIVE RECEPTOR AGONISTS IN MEDICAL TREATMENT | PFIZER PRODUCTS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| US-20020165255-A1 | Osteoporosis compounds | CAMERON KIMBERLY O (US) | 2002-11-07 | — | — | US | disclosed |
| US-6376502-B1 | PROSTAGLANDIN AGONISTS ARE USEFUL FOR THE TREATMENT OF BONE DISORDERS INCLUDING OSTEOPOROSIS. | PFIZER INC. | 2002-04-23 | — | — | US | disclosed |
| US-6124314-A | A PROSTAGLANDIN AGONISTS FOR TREATING VERTEBRATE BONE DISORDERS | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0911321-A2 | Compounds for the treatment of osteoporosis | PFIZER INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | SLC7A5 252/4885LOXL2 4413/4885ALDH1A1 2254/4885 |
| US-20200207721-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | SLC7A5 644/4885LOXL2 1982/4885ALDH1A1 171/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | SLC7A5 1341/4885LOXL2 3342/4885ALDH1A1 4236/4885 |
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | SLC7A5 252/4885LOXL2 4413/4885ALDH1A1 2254/4885 |
| US-20020165255-A1 | Osteoporosis compounds | PTGER1, PTGIR, PTGER4 | SLC7A5 3090/4885LOXL2 405/4885ALDH1A1 2288/4885 |
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PTGER2, PTGES2, PTGFR | SLC7A5 4539/4885LOXL2 125/4885ALDH1A1 3293/4885 |
| US-11254644-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | ACMSD, GLS, ALDH7A1 | SLC7A5 644/4885LOXL2 1982/4885ALDH1A1 171/4885 |
| US-20030078261-A1 | Prostaglandin agonists | PTGER1, PTGER4, PTGIR | SLC7A5 3466/4885LOXL2 356/4885ALDH1A1 1987/4885 |
| US-11261201-B2 | TRNA synthetase inhibitors | TRMT1, AARS1, GARS1 | SLC7A5 252/4885LOXL2 4413/4885ALDH1A1 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.